当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

Abstract：

:Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor. Here, we characterize the activity of two novel, highly selective Syk inhibitors, PRT318 and P505-15, in assays that model CLL interactions with the microenvironment. PRT318 and P505-15 effectively antagonize CLL cell survival after BCR triggering and in nurse-like cell-co-cultures. Moreover, they inhibit BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT318 and P505-15 furthermore inhibit Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering. These findings demonstrate that the selective Syk inhibitors PRT318 and P505-15 are highly effective for inhibition of CLL survival and tissue homing circuits, and support the therapeutic development of these agents in patients with CLL, other B-cell malignancies and autoimmune disorders.

journal_name

Leukemia

journal_title

Leukemia

authors

Hoellenriegel J,Coffey GP,Sinha U,Pandey A,Sivina M,Ferrajoli A,Ravandi F,Wierda WG,O'Brien S,Keating MJ,Burger JA

doi

10.1038/leu.2012.24

subject

Has Abstract

pub_date

2012-07-01 00:00:00

pages

1576-83

issue

7

eissn

0887-6924

issn

1476-5551

pii

leu201224

journal_volume

26

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

    abstract：:Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphobla...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.78

    authors： Reynolds C,Roderick JE,LaBelle JL,Bird G,Mathieu R,Bodaar K,Colon D,Pyati U,Stevenson KE,Qi J,Harris M,Silverman LB,Sallan SE,Bradner JE,Neuberg DS,Look AT,Walensky LD,Kelliher MA,Gutierrez A

    更新日期：2014-09-01 00:00:00

  • Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia.

    abstract：:The t(9;11)(p21;q23) has been associated with characteristic clinical features and a superior treatment outcome in previously untreated pediatric acute myeloblastic leukemia (AML), but has not been well studied in children with secondary AML. This translocation was detected in 6.7% of de novo and 46% of secondary AML ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Sandoval C,Head DR,Mirro J Jr,Behm FG,Ayers GD,Raimondi SC

    更新日期：1992-06-01 00:00:00

  • Expression of human CSF-1 receptor induces CSF-1-dependent proliferation in murine myeloid but not in T-lymphoid cells.

    abstract：:The receptor for human macrophage colony stimulating factor (CSF-1R) was introduced into hematopoietic cell lines of myeloid and T-lymphoid origin, both of which normally do not express the CSF-1R. Infection of an interleukin-3 (IL-3)-dependent mouse myeloid cell line (FDC-P1) with a high titer retroviral vector expre...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： von Rüden T,Mouchiroud G,Bourette RP,Ouazana R,Blanchet JP,Wagner EF

    更新日期：1991-01-01 00:00:00

  • Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

    abstract：:Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0334-3

    authors： Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

    更新日期：2019-06-01 00:00:00

  • Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

    abstract：:The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)-chronic myelogenous leukemia, polycythemia vera (PV), essential thro...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404955

    authors： Tefferi A,Vardiman JW

    更新日期：2008-01-01 00:00:00

  • Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment.

    abstract：:Interferon-alpha produces a complete hematologic and cytogenetic remission in approximately 20% of patients with chronic myelogenous leukemia (CML). In this study, we applied fluorescent in situ hybridization (FISH) methodology to examine the possibility that a low level of proliferating Philadelphia-chromosome-positi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Zhao L,Kantarjian HM,Van Oort J,Cork A,Trujillo JM,Liang JC

    更新日期：1993-02-01 00:00:00

  • Secondary acute lymphoblastic leukaemia with 4:11 translocation following treatment for Hodgkin's disease: case report and review of the literature.

    abstract：:It is apparent that treatment of Hodgkin's disease can be complicated by the development of secondary leukaemia. Most such leukaemias are of the non-lymphocytic type. We describe here a patient treated for Hodgkin's disease with chemo- and radiotherapy who developed secondary acute lymphoblastic leukaemia with a non-r...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Lennard A,Jackson GH,Carey PJ,Bown N,Middleton P,Proctor SJ

    更新日期：1991-07-01 00:00:00

  • Identification of T-cell epitopes for cancer immunotherapy.

    abstract：:The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins. Our...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404787

    authors： Kessler JH,Melief CJ

    更新日期：2007-09-01 00:00:00

  • Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

    abstract：:The outcome of a cohort of 218 consecutive patients who failed to respond to a single course of standard daunorubicin plus ARAC (three + seven) induction regimen has been retrospectively evaluated to assess the characteristics of this group of AML patients and the effectiveness of second-line induction programs. Seven...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Liso V,Iacopino P,Avvisati G,Petti MC,Broccia G,Carotenuto M,Falda M,Fazi P,Lazzarino M,Leoni P,Mirto S,Pucci G,Nobile F,Nosari AM,Specchia G,Stasi R,Tabilio A,Mandelli F

    更新日期：1996-09-01 00:00:00

  • Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.

    abstract：:Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relapse, but the role of scheduling and its impact on outcome are not known. In a prospective, randomized multicente...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/leu.2012.352

    authors： Pfeifer H,Wassmann B,Bethge W,Dengler J,Bornhäuser M,Stadler M,Beelen D,Vucinic V,Burmeister T,Stelljes M,Faul C,Dreger P,Kiani A,Schäfer-Eckart K,Schwerdtfeger R,Lange E,Kubuschok B,Horst HA,Gramatzki M,Brück P,S

    更新日期：2013-06-01 00:00:00

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

    abstract：:Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with dif...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2012.336

    authors： Fernández de Larrea C,Kyle RA,Durie BG,Ludwig H,Usmani S,Vesole DH,Hajek R,San Miguel JF,Sezer O,Sonneveld P,Kumar SK,Mahindra A,Comenzo R,Palumbo A,Mazumber A,Anderson KC,Richardson PG,Badros AZ,Caers J,Cavo M,Le

    更新日期：2013-04-01 00:00:00

  • Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.

    abstract：:Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404734

    authors： Straube C,Wehner R,Wendisch M,Bornhäuser M,Bachmann M,Rieber EP,Schmitz M

    更新日期：2007-07-01 00:00:00

  • Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.

    abstract：:Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are scarce. The aim of this nationwide population-based study is to assess trends in primary therapy and relative survival (RS) during 1989-2017. We included 9,985 patients with cHL. Radiotherapy alone was virtually not appl...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0875-0

    authors： Driessen J,Visser O,Zijlstra JM,Lugtenburg PJ,Plattel WJ,Kersten MJ,Dinmohamed AG

    更新日期：2020-05-28 00:00:00

  • High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

    abstract：:Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here we isolated a high-affinity (HA) f...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.35

    authors： Lynn RC,Feng Y,Schutsky K,Poussin M,Kalota A,Dimitrov DS,Powell DJ Jr

    更新日期：2016-06-01 00:00:00

  • Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

    abstract：:Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, including the FLT3-ITD allelic ratio. PRT consisted of reduce...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.183

    authors： Versluis J,In 't Hout FE,Devillier R,van Putten WL,Manz MG,Vekemans MC,Legdeur MC,Passweg JR,Maertens J,Kuball J,Biemond BJ,Valk PJ,van der Reijden BA,Meloni G,Schouten HC,Vellenga E,Pabst T,Willemze R,Löwenberg B,O

    更新日期：2017-01-01 00:00:00

  • The murine long-term multi-lineage renewal marrow stem cell is a cycling cell.

    abstract：:Prevailing wisdom holds that hematopoietic stem cells (HSCs) are predominantly quiescent. Although HSC cycle status has long been the subject of scrutiny, virtually all marrow stem cell research has been based on studies of highly purified HSCs. Here we explored the cell cycle status of marrow stem cells in un-separat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.252

    authors： Goldberg LR,Dooner MS,Johnson KW,Papa EF,Pereira MG,Del Tatto M,Adler DM,Aliotta JM,Quesenberry PJ

    更新日期：2014-04-01 00:00:00

  • A paradigm shift in myelodysplastic syndromes.

    abstract：:A poorly defined transforming event(s) affects the pluripotential bone marrow (BM) stem cell in myelodysplastic syndromes (MDS), conferring a growth advantage upon it which leads eventually to monoclonal hematopoiesis. The progeny of this transformed ancestor undergo recognizable albeit dysplastic maturation. We propo...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Raza A,Mundle S,Shetty V,Alvi S,Chopra H,Span L,Parcharidou A,Dar S,Venugopal P,Borok R,Gezer S,Showel J,Loew J,Robin E,Rifkin S,Alston D,Hernandez B,Shah R,Kaizer H,Gregory S,Preisler H

    更新日期：1996-10-01 00:00:00

  • Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype.

    abstract：:Two hundred and forty-four untreated acute myelogenous leukemia (AML) patients with unfavorable karyotypes and 109 others with favorable aneuploid karyotypes were used to evaluate the prognostic significance of having both normal and abnormal metaphases (AN) vs only abnormal metaphases (AA) at AML presentation. The AA...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Ghaddar HM,Pierce S,Reed P,Estey EH

    更新日期：1995-05-01 00:00:00

  • Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

    abstract：:Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by chronic proliferation of hematopoietic progenitors. We studied the telomere length (TL) of 335 MPN patients and 93 gender- and age-matched controls using a quantitative PCR method (relative TL calculated as the ratio of the amount of t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.319

    authors： Bernard L,Belisle C,Mollica L,Provost S,Roy DC,Gilliland DG,Levine RL,Busque L

    更新日期：2009-02-01 00:00:00

  • Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia.

    abstract：:Ninety-five percent of radiation-induced murine myeloid leukemias contain chromosome 2 aberrations. A dominant molecular defect has not yet been identified: both deletions and breakpoint-specific events have been postulated. We have generated a model in which chromosome 2 lesions have been generated in vitro in a clon...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Alexander BJ,Rasko JE,Morahan G,Cook WD

    更新日期：1995-12-01 00:00:00

  • Immunoglobulin and T cell receptor gene rearrangement and expression in B cell acute lymphoblastic leukemia.

    abstract：:Immunoglobulin and T cell receptor gene rearrangement and expression were investigated within B cell acute lymphoblastic leukemias (ALLs) that are thought to be representative of the early stages of normal human B cell development. Although the immunoglobulin heavy chain locus is rearranged in leukemic cells from all ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Kinnon C,Katz F

    更新日期：1989-11-01 00:00:00

  • Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias.

    abstract：:Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs). Here, we report the analysis for activating NOTCH1 mutations in a large number of acute myeloid leukemia (AML) primary samples and cell lines. We found activating mutations in NOTCH1 in a single M0 primary AML sample...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404409

    authors： Palomero T,McKenna K,O-Neil J,Galinsky I,Stone R,Suzukawa K,Stiakaki E,Kalmanti M,Fox EA,Caligiuri MA,Aster JC,Look AT,Ferrando AA

    更新日期：2006-11-01 00:00:00

  • In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.

    abstract：:Fludarabine phosphate (2-F-ara-AMP) is an adenine nucleoside analogue that shows significant activity against chronic lymphocytic leukemia and indolent lymphoma. We assessed the cytotoxic interaction produced by the combination of the active metabolite of fludarabine phosphate, fludarabine (9-beta-D-arabinofuranosyl-2...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401684

    authors： Kano Y,Akutsu M,Tsunoda S,Suzuki K,Ichikawa A,Furukawa Y,Bai L,Kon K

    更新日期：2000-03-01 00:00:00

  • Identification of immunoglobulin lambda isotype gene rearrangements by Southern blot analysis.

    abstract：:The human immunoglobulin lambda (Ig(lambda)) gene locus contains seven homologous C(lambda) exons which are organized in a tandem array, each of which is preceded by a single J(lambda) gene segment. The J-C(lambda)1, J-C(lambda)2, J-C(lambda)3, and J-C(lambda)7 are functional gene regions and encode for the four Ig(la...

    journal_title：Leukemia

    pub_type：

    doi：

    authors： Tümkaya T,Beishuizen A,Wolvers-Tettero IL,van Dongen JJ

    更新日期：1996-11-01 00:00:00

  • Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation.

    abstract：:Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.246

    authors： Forrest AR,Kanamori-Katayama M,Tomaru Y,Lassmann T,Ninomiya N,Takahashi Y,de Hoon MJ,Kubosaki A,Kaiho A,Suzuki M,Yasuda J,Kawai J,Hayashizaki Y,Hume DA,Suzuki H

    更新日期：2010-02-01 00:00:00

  • LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.

    abstract：:The predominant usage of VH4-34 and V3-21 and reports of stereotyped CDR3s suggest a shared antigenic target of B-cell receptors (BCR) from mantle cell lymphomas (MCL). To identify the target antigens of MCL-BCRs, BCRs from 21 patients and seven MCL cell lines were recombinantly expressed and used for antigen screenin...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0182-1

    authors： Thurner L,Hartmann S,Fadle N,Kemele M,Bock T,Bewarder M,Regitz E,Neumann F,Nimmesgern A,von Müller L,Pott C,Kim YJ,Bohle RM,Wasik M,Schuster SJ,Hansmann ML,Preuss KD,Pfreundschuh M

    更新日期：2019-01-01 00:00:00

  • Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.

    abstract：:Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Griffiths SD,Cawley JC

    更新日期：1988-06-01 00:00:00

  • In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells.

    abstract：:Granulocyte-macrophage colony-stimulating factor, (GM-CSF) was given at 8 micrograms/kg daily by continuous i.v. infusion for 72 h to six patients with acute myeloid leukemia (AML) in expansion and one with chronic myeloid leukemia in blastic crisis to determine whether it was possible to augment the proliferative act...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Aglietta M,De Felice L,Stacchini A,Petti MC,Bianchi AC,Aloe Spiriti MA,Sanavio F,Apra F,Piacibello W,Stern AC

    更新日期：1991-11-01 00:00:00

  • Quantitative analysis of Op18 phosphorylation in childhood acute leukemia.

    abstract：:Oncoprotein 18 (Op18) is a major cystolic phosphoprotein constituent of leukemia cells. There is cumulative evidence that suggests a role for Op18 in integrating signals from diverse pathways involved in cell growth. Op18 phosphorylation is induced with proliferation in a variety of cell types, and is essential for ce...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400792

    authors： Melhem R,Hailat N,Kuick R,Hanash SM

    更新日期：1997-10-01 00:00:00

  • High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

    abstract：:High-dose methotrexate (Hd-MTX) therapy has recently been applied to the treatment of adult acute lymphoblastic leukemia (ALL) based on pediatric protocols; however, its effectiveness for adult ALL has not yet been confirmed in a rigorous manner. We herein conducted a randomized phase III trial comparing Hd-MTX therap...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/leu.2017.283

    authors： Sakura T,Hayakawa F,Sugiura I,Murayama T,Imai K,Usui N,Fujisawa S,Yamauchi T,Yujiri T,Kakihana K,Ito Y,Kanamori H,Ueda Y,Miyata Y,Kurokawa M,Asou N,Ohnishi K,Ohtake S,Kobayashi Y,Matsuo K,Kiyoi H,Miyazaki Y,Na

    更新日期：2018-03-01 00:00:00